Goldman Sachs Group Inc. Purchases 54,783 Shares of GoodRx Holdings, Inc. $GDRX

Goldman Sachs Group Inc. boosted its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 7.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 783,378 shares of the company’s stock after acquiring an additional 54,783 shares during the quarter. Goldman Sachs Group Inc. owned 0.22% of GoodRx worth $3,455,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in GDRX. 8 Knots Management LLC bought a new position in GoodRx in the first quarter valued at approximately $8,106,000. EVR Research LP increased its stake in GoodRx by 243.3% in the first quarter. EVR Research LP now owns 1,300,000 shares of the company’s stock valued at $5,733,000 after acquiring an additional 921,337 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of GoodRx by 98.1% during the fourth quarter. Two Sigma Investments LP now owns 722,374 shares of the company’s stock worth $3,359,000 after buying an additional 357,674 shares during the last quarter. PDT Partners LLC grew its stake in shares of GoodRx by 1,351.3% during the first quarter. PDT Partners LLC now owns 370,219 shares of the company’s stock worth $1,633,000 after buying an additional 344,709 shares during the last quarter. Finally, Two Sigma Advisers LP grew its stake in shares of GoodRx by 69.1% during the fourth quarter. Two Sigma Advisers LP now owns 754,000 shares of the company’s stock worth $3,506,000 after buying an additional 308,000 shares during the last quarter. 63.77% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GDRX. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $6.00 target price on shares of GoodRx in a research note on Monday, August 11th. Raymond James Financial cut shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a research note on Friday, August 8th. Five research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $5.80.

Insider Activity

In other news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $4.05, for a total transaction of $64,864.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.53% of the stock is currently owned by insiders.

GoodRx Trading Up 3.2%

NASDAQ:GDRX opened at $4.23 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.21 and a current ratio of 4.21. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of 42.30, a price-to-earnings-growth ratio of 1.79 and a beta of 1.23. GoodRx Holdings, Inc. has a 52 week low of $3.31 and a 52 week high of $7.44. The firm has a 50-day moving average price of $4.38 and a two-hundred day moving average price of $4.42.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). The firm had revenue of $203.07 million during the quarter, compared to analysts’ expectations of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the business posted $0.08 EPS. On average, equities analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.